Search

Your search keyword '"VALERIO, Maria Rosaria"' showing total 14 results
Start Over Author "VALERIO, Maria Rosaria" Publisher springer science and business media llc
14 results on '"VALERIO, Maria Rosaria"'

1. Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Author

Fabi, Alessandra, primary, Carbognin, Luisa, additional, Botticelli, Andrea, additional, Paris, Ida, additional, Fuso, Paola, additional, Savastano, Maria Cristina, additional, La Verde, Nicla, additional, Strina, Carla, additional, Pedersini, Rebecca, additional, Guarino, Stefania, additional, Curigliano, Giuseppe, additional, Criscitiello, Carmen, additional, Raffaele, Mimma, additional, Beano, Alessandra, additional, Franco, Antonio, additional, Valerio, Maria Rosaria, additional, Verderame, Francesco, additional, Fontana, Andrea, additional, Haspinger, Eva Regina, additional, Caldara, Alessia, additional, Di Leone, Alba, additional, Tortora, Giampaolo, additional, Giannarelli, Diana, additional, and Scambia, Giovanni, additional

Published
2024
Full Text
View/download PDF

2. Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Author

Fabi, Alessandra, primary, Carbognin, Luisa, additional, Botticelli, Andrea, additional, Paris, Ida, additional, Fuso, Paolo, additional, Savastano, Maria Cristina, additional, La Verde, Nicla, additional, Strina, Carla, additional, Pedersini, Rebecca, additional, Guarino, Stefania, additional, Curigliano, Giuseppe, additional, Criscitiello, Carmen, additional, Raffaele, Mimma, additional, Beano, Alessandra, additional, Franco, Antonio, additional, Valerio, Maria Rosaria, additional, Verderame, Francesco, additional, Fontana, Andrea, additional, Haspinger, Eva Regina, additional, Caldara, Alessia, additional, Di Leone, Alba, additional, Tortora, Giampaolo, additional, Giannarelli, Diana, additional, and Scambia, Giovanni, additional

Published
2023
Full Text
View/download PDF

3. Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Author

Fabi, Alessandra, primary, Carbognin, Luisa, additional, Botticelli, Andrea, additional, Paris, Ida, additional, Fuso, Paolo, additional, Savastano, Maria Cristina, additional, La Verde, Nicla, additional, Strina, Carla, additional, Pedersini, Rebecca, additional, Guarino, Stefania, additional, Curigliano, Giuseppe, additional, Criscitiello, Carmen, additional, Raffaele, Mimma, additional, Beano, Alessandra, additional, Franco, Antonio, additional, Valerio, Maria Rosaria, additional, Verderame, Francesco, additional, Fontana, Andrea, additional, Haspinger, Eva Regina, additional, Caldara, Alessia, additional, Di Leone, Alba, additional, Tortora, Giampaolo, additional, Giannarelli, Diana, additional, and Scambia, Giovanni, additional

Published
2023
Full Text
View/download PDF

6. Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)

Author

Torrisi, Rosalba, primary, Palumbo, Raffaella, additional, De Sanctis, Rita, additional, Vici, Patrizia, additional, Bianchi, Giulia Valeria, additional, Cortesi, Laura, additional, Leonardi, Vita, additional, Gueli, Rossana, additional, Fabi, Alessandra, additional, Valerio, Maria Rosaria, additional, Gambaro, Anna Rita, additional, Tagliaferri, Barbara, additional, Pizzuti, Laura, additional, Cazzaniga, Marina Elena, additional, and Santoro, Armando, additional

Published
2021
Full Text
View/download PDF

7. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

Author

Pizzuti, Laura, primary, Barba, Maddalena, additional, Mazzotta, Marco, additional, Krasniqi, Eriseld, additional, Maugeri-Saccà, Marcello, additional, Gamucci, Teresa, additional, Berardi, Rossana, additional, Livi, Lorenzo, additional, Ficorella, Corrado, additional, Natoli, Clara, additional, Cortesi, Enrico, additional, Generali, Daniele, additional, La Verde, Nicla, additional, Cassano, Alessandra, additional, Bria, Emilio, additional, Moscetti, Luca, additional, Michelotti, Andrea, additional, Adamo, Vincenzo, additional, Zamagni, Claudio, additional, Tonini, Giuseppe, additional, Sergi, Domenico, additional, Marinelli, Daniele, additional, Paoletti, Giancarlo, additional, Tomao, Silverio, additional, Botticelli, Andrea, additional, Marchetti, Paolo, additional, Tinari, Nicola, additional, Grassadonia, Antonino, additional, Valerio, Maria Rosaria, additional, Mirabelli, Rosanna, additional, Fabbri, Maria Agnese, additional, D’Ostilio, Nicola, additional, Veltri, Enzo, additional, Corsi, Domenico, additional, Garrone, Ornella, additional, Paris, Ida, additional, Sarobba, Giuseppina, additional, Meattini, Icro, additional, Pistelli, Mirco, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Garufi, Carlo, additional, Russo, Antonio, additional, Cazzaniga, Marina, additional, Del Medico, Pietro, additional, Roselli, Mario, additional, Vaccaro, Angela, additional, Perracchio, Letizia, additional, di Benedetto, Anna, additional, Daralioti, Theodora, additional, Sperduti, Isabella, additional, De Maria, Ruggero, additional, Di Leo, Angelo, additional, Sanguineti, Giuseppe, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2021
Full Text
View/download PDF

8. Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer

Author

Gebbia, Vittorio, primary, Guarini, Aurelia, additional, Piazza, Dario, additional, Bertani, Alessandro, additional, Spada, Massimiliano, additional, Verderame, Francesco, additional, Sergi, Concetta, additional, Potenza, Enrico, additional, Fazio, Ivan, additional, Blasi, Livio, additional, La Sala, Alba, additional, Mortillaro, Gianluca, additional, Roz, Elena, additional, Marchese, Roberto, additional, Chiarenza, Maurizio, additional, Soto-Parra, Hector, additional, Valerio, Maria Rosaria, additional, Agneta, Giuseppe, additional, Amato, Carmela, additional, Lipari, Helga, additional, Baldari, Sergio, additional, Ferraù, Francesco, additional, Di Grazia, Alfio, additional, Mancuso, Gianfranco, additional, Rizzo, Sergio, additional, and Firenze, Alberto, additional

Published
2021
Full Text
View/download PDF

9. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Author

Bon, Giulia, primary, Pizzuti, Laura, additional, Laquintana, Valentina, additional, Loria, Rossella, additional, Porru, Manuela, additional, Marchiò, Caterina, additional, Krasniqi, Eriseld, additional, Barba, Maddalena, additional, Maugeri-Saccà, Marcello, additional, Gamucci, Teresa, additional, Berardi, Rossana, additional, Livi, Lorenzo, additional, Ficorella, Corrado, additional, Natoli, Clara, additional, Cortesi, Enrico, additional, Generali, Daniele, additional, La Verde, Nicla, additional, Cassano, Alessandra, additional, Bria, Emilio, additional, Moscetti, Luca, additional, Michelotti, Andrea, additional, Adamo, Vincenzo, additional, Zamagni, Claudio, additional, Tonini, Giuseppe, additional, Barchiesi, Giacomo, additional, Mazzotta, Marco, additional, Marinelli, Daniele, additional, Tomao, Silverio, additional, Marchetti, Paolo, additional, Valerio, Maria Rosaria, additional, Mirabelli, Rosanna, additional, Russo, Antonio, additional, Fabbri, Maria Agnese, additional, D’Ostilio, Nicola, additional, Veltri, Enzo, additional, Corsi, Domenico, additional, Garrone, Ornella, additional, Paris, Ida, additional, Sarobba, Giuseppina, additional, Giotta, Francesco, additional, Garufi, Carlo, additional, Cazzaniga, Marina, additional, Del Medico, Pietro, additional, Roselli, Mario, additional, Sanguineti, Giuseppe, additional, Sperduti, Isabella, additional, Sapino, Anna, additional, De Maria, Ruggero, additional, Leonetti, Carlo, additional, Di Leo, Angelo, additional, Ciliberto, Gennaro, additional, Falcioni, Rita, additional, and Vici, Patrizia, additional

Published
2020
Full Text
View/download PDF

11. Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

Author

Amadori, Dino, primary, Silvestrini, Rosella, additional, De Lena, Mario, additional, Boccardo, Francesco, additional, Rocca, Andrea, additional, Scarpi, Emanuela, additional, Schittulli, Francesco, additional, Brandi, Mario, additional, Maltoni, Roberta, additional, Serra, Patrizia, additional, Ponzone, Riccardo, additional, Biglia, Nicoletta, additional, Gianni, Lorenzo, additional, Tienghi, Amelia, additional, Valerio, Maria Rosaria, additional, Bonginelli, Paola, additional, Amaducci, Laura, additional, Faedi, Marina, additional, Baldini, Editta, additional, and Paradiso, Angelo, additional

Published
2010
Full Text
View/download PDF

12. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

Author

Pignata, Sandro, primary, De Placido, Sabino, additional, Biamonte, Rosalbino, additional, Scambia, Giovanni, additional, Di Vagno, Giovanni, additional, Colucci, Giuseppe, additional, Febbraro, Antonio, additional, Marinaccio, Marco, additional, Vernaglia Lombardi, Alessandra, additional, Manzione, Luigi, additional, Cartenì, Giacomo, additional, Nardi, Mario, additional, Danese, Saverio, additional, Valerio, Maria Rosaria, additional, de Matteis, Andrea, additional, Massidda, Bruno, additional, Gasparini, Giampietro, additional, Di Maio, Massimo, additional, Pisano, Carmela, additional, and Perrone, Francesco, additional

Published
2006
Full Text
View/download PDF

13. A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer

Author

Calò, Valentina, primary, Agnese, Valentina, additional, Gargano, Grazia, additional, Corsale, Simona, additional, Gregorio, Valter, additional, Cascio, Sandra, additional, Cammareri, Patrizia, additional, Bruno, Loredana, additional, Augello, Claudia, additional, Gullo, Arianna, additional, Sisto, Pasqua Sandra, additional, Badalamenti, Giuseppe, additional, Valerio, Maria Rosaria, additional, Napoli, Liborio, additional, Gebbia, Nicola, additional, Bazan, Viviana, additional, and Russo, Antonio, additional

Published
2005
Full Text
View/download PDF

14. Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)

Author

Laura Pizzuti, Laura Cortesi, Barbara Tagliaferri, Armando Santoro, Patrizia Vici, A. Gambaro, Rita De Sanctis, Raffaella Palumbo, Alessandra Fabi, Vita Leonardi, Rosalba Torrisi, Maria Rosaria Valerio, Rossana Gueli, Marina Elena Cazzaniga, Giulia Bianchi, Torrisi, R, Palumbo, R, De Sanctis, R, Vici, P, Bianchi, G, Cortesi, L, Leonardi, V, Gueli, R, Fabi, A, Valerio, M, Gambaro, A, Tagliaferri, B, Pizzuti, L, Cazzaniga, M, Santoro, A, Torrisi, Rosalba, Palumbo, Raffaella, De Sanctis, Rita, Vici, Patrizia, Bianchi, Giulia Valeria, Cortesi, Laura, Leonardi, Vita, Gueli, Rossana, Fabi, Alessandra, Valerio, Maria Rosaria, Gambaro, Anna Rita, Tagliaferri, Barbara, Pizzuti, Laura, Cazzaniga, Marina Elena, and Santoro, Armando

Subjects
HER2 positive, Oncology, Cancer Research, medicine.medical_specialty, Settore MED/06 - Oncologia Medica, Receptor, ErbB-2, Advanced breast, Breast Neoplasms, Breast cancer, Maintenance therapy, Trastuzumab, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Fulvestrant, Retrospective Studies, Hormone receptor positive, business.industry, Cancer, Middle Aged, medicine.disease, Italy, Cohort, Advanced breast cancer, Female, Pertuzumab, business, medicine.drug
Abstract

Purpose: The most appropriate therapy for HR + /HER2-positive (HER2 +) advanced breast cancer (ABC) is a matter of debate. Co-targeting of both receptors represents an attractive strategy to overcome the cross-talk between them. Methods: The HERMIONE 9 is an observational retrospective multicentric study which aimed to describe the clinical outcome of patients with HR + /HER2 + ABC who received the combination of Fulvestrant (F) and Trastuzumab (T) as part of their routine treatment at 10 Italian Institutions. Results: Eighty-seven patients were included. Median age was 63 (range, 35–87) years. The median number of previous treatments was 3 (range, 0–10) and F and T were administered as ≥ 3rd line in 67 patients. Among the 86 evaluable patients, 6 (6.9%) achieved CR, 18 (20.7%) PR, and 44 (50.6%) had SD ≥ 24 weeks with an overall CBR of 78.2%. At a median follow-up of 33.6 months, mPFS of the entire cohort was 12.9 months (range, 2.47–128.67). No difference was observed in mPFS between patients treated after progression or as maintenance therapy (mPFS 12.9 and 13.9 months in 64 and 23 patients, respectively), neither considering the number of previous treatment lines (≤ 3 or < 3). Conclusion: The combination of F and T was active in this cohort at poor prognosis and deserves further investigations possibly in combination with pertuzumab in patients with high ER expression.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results